<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=799&amp;modal=1&amp;valnames=exclusion_criteria&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="494265" class="table-">
                
                <td>June 25, 2024, noon</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria">
            1. patients participating in some other clinical trial for covid-19 infection.
2. patients who are receiving treatment with antivirals, interleukin 6 receptor inhibitors or immunomodulatory drugs for covid-19.
3. patients who are receiving treatment with chloroquine and derivatives.
4. evidence of multi-organ failure.
5. patients who require support with mechanical ventilation (invasive or non-invasive) at the time of inclusion.
6. d-dimer\&gt; 4 x unl.
7. hb \&lt;9 g / dl.
8. neutrophils \&lt;1000 / mm3.
9. platelets \&lt;100,000 / mm3.
10. lymphopenia \&lt;800 / μl.
11. got / gpt\&gt; 3 x unl.
12. bilirubin\&gt; 1 x unl.
13. cpk\&gt; 2.5 x unl.
14. creatinine clearance \&lt;30ml / min.
15. troponin elevation\&gt; 1.5 x uln.
16. clinically relevant heart disease (nyha\&gt; 2).
17. clinically relevant arrhythmia or previous history / presence of prolonged qt-qtc ≥ 450 ms.
18. pre-existing neuropathies of any type ≥ grade 2.
19. hypersensitivity to the active substance or to any of its excipients (macrogol glycerol ricinoleate and ethanol).
20. patients who require or are being treated with potent cyp3a4 inhibitors and inducers.
21. patients who for any reason should not be included in the study according to the evaluation of the research team.
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria validated">
            1. patients participating in some other clinical trial for covid-19 infection.
2. patients who are receiving treatment with antivirals, interleukin 6 receptor inhibitors or immunomodulatory drugs for covid-19.
3. patients who are receiving treatment with chloroquine and derivatives.
4. evidence of multi-organ failure.
5. patients who require support with mechanical ventilation (invasive or non-invasive) at the time of inclusion.
6. d-dimer\&gt; 4 x unl.
7. hb \&lt;9 g / dl.
8. neutrophils \&lt;1000 / mm3.
9. platelets \&lt;100,000 / mm3.
10. lymphopenia \&lt;800 / μl.
11. got / gpt\&gt; 3 x unl.
12. bilirubin\&gt; 1 x unl.
13. cpk\&gt; 2.5 x unl.
14. creatinine clearance \&lt;30ml / min.
15. troponin elevation\&gt; 1.5 x uln.
16. clinically relevant heart disease (nyha\&gt; 2).
17. clinically relevant arrhythmia or previous history / presence of prolonged qt-qtc ≥ 450 ms.
18. pre-existing neuropathies of any type ≥ grade 2.
19. hypersensitivity to the active substance or to any of its excipients (macrogol glycerol ricinoleate and ethanol).
20. patients who require or are being treated with potent cyp3a4 inhibitors and inducers.
21. patients who for any reason should not be included in the study according to the evaluation of the research team.
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="154591" class="table-">
                
                <td>Nov. 16, 2021, 6:30 p.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria">
            patients participating in some other clinical trial for covid-19 infection.
patients who are receiving treatment with antivirals, interleukin 6 receptor inhibitors or immunomodulatory drugs for covid-19.
patients who are receiving treatment with chloroquine and derivatives.
evidence of multi-organ failure.
patients who require support with mechanical ventilation (invasive or non-invasive) at the time of inclusion.
d-dimer&gt; 4 x unl.
hb &lt;9 g / dl.
neutrophils &lt;1000 / mm3.
platelets &lt;100,000 / mm3.
lymphopenia &lt;800 / μl.
got / gpt&gt; 3 x unl.
bilirubin&gt; 1 x unl.
cpk&gt; 2.5 x unl.
creatinine clearance &lt;30ml / min.
troponin elevation&gt; 1.5 x uln.
clinically relevant heart disease (nyha&gt; 2).
clinically relevant arrhythmia or previous history / presence of prolonged qt-qtc ≥ 450 ms.
pre-existing neuropathies of any type ≥ grade 2.
hypersensitivity to the active substance or to any of its excipients (macrogol glycerol ricinoleate and ethanol).
patients who require or are being treated with potent cyp3a4 inhibitors and inducers.
patients who for any reason should not be included in the study according to the evaluation of the research team.
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria validated">
            patients participating in some other clinical trial for covid-19 infection.
patients who are receiving treatment with antivirals, interleukin 6 receptor inhibitors or immunomodulatory drugs for covid-19.
patients who are receiving treatment with chloroquine and derivatives.
evidence of multi-organ failure.
patients who require support with mechanical ventilation (invasive or non-invasive) at the time of inclusion.
d-dimer&gt; 4 x unl.
hb &lt;9 g / dl.
neutrophils &lt;1000 / mm3.
platelets &lt;100,000 / mm3.
lymphopenia &lt;800 / μl.
got / gpt&gt; 3 x unl.
bilirubin&gt; 1 x unl.
cpk&gt; 2.5 x unl.
creatinine clearance &lt;30ml / min.
troponin elevation&gt; 1.5 x uln.
clinically relevant heart disease (nyha&gt; 2).
clinically relevant arrhythmia or previous history / presence of prolonged qt-qtc ≥ 450 ms.
pre-existing neuropathies of any type ≥ grade 2.
hypersensitivity to the active substance or to any of its excipients (macrogol glycerol ricinoleate and ethanol).
patients who require or are being treated with potent cyp3a4 inhibitors and inducers.
patients who for any reason should not be included in the study according to the evaluation of the research team.
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="25553" class="table-">
                
                <td>Oct. 26, 2020, 11:31 p.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria">
            1. patients participating in some other clinical trial for covid-19 infection.

          2. patients who are receiving treatment with antivirals, interleukin 6 receptor
             inhibitors or immunomodulatory drugs for covid-19.

          3. patients who are receiving treatment with chloroquine and derivatives.

          4. evidence of multi-organ failure.

          5. patients who require support with mechanical ventilation (invasive or non-invasive) at
             the time of inclusion.

          6. d-dimer&gt; 4 x unl.

          7. hb &lt;9 g / dl.

          8. neutrophils &lt;1000 / mm3.

          9. platelets &lt;100,000 / mm3.

         10. lymphopenia &lt;800 / μl.

         11. got / gpt&gt; 3 x unl.

         12. bilirubin&gt; 1 x unl.

         13. cpk&gt; 2.5 x unl.

         14. creatinine clearance &lt;30ml / min.

         15. troponin elevation&gt; 1.5 x uln.

         16. clinically relevant heart disease (nyha&gt; 2).

         17. clinically relevant arrhythmia or previous history / presence of prolonged qt-qtc ≥
             450 ms.

         18. pre-existing neuropathies of any type ≥ grade 2.

         19. hypersensitivity to the active substance or to any of its excipients (macrogol
             glycerol ricinoleate and ethanol).

         20. patients who require or are being treated with potent cyp3a4 inhibitors and inducers.

         21. patients who for any reason should not be included in the study according to the
             evaluation of the research team.
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria validated">
            1. patients participating in some other clinical trial for covid-19 infection.

          2. patients who are receiving treatment with antivirals, interleukin 6 receptor
             inhibitors or immunomodulatory drugs for covid-19.

          3. patients who are receiving treatment with chloroquine and derivatives.

          4. evidence of multi-organ failure.

          5. patients who require support with mechanical ventilation (invasive or non-invasive) at
             the time of inclusion.

          6. d-dimer&gt; 4 x unl.

          7. hb &lt;9 g / dl.

          8. neutrophils &lt;1000 / mm3.

          9. platelets &lt;100,000 / mm3.

         10. lymphopenia &lt;800 / μl.

         11. got / gpt&gt; 3 x unl.

         12. bilirubin&gt; 1 x unl.

         13. cpk&gt; 2.5 x unl.

         14. creatinine clearance &lt;30ml / min.

         15. troponin elevation&gt; 1.5 x uln.

         16. clinically relevant heart disease (nyha&gt; 2).

         17. clinically relevant arrhythmia or previous history / presence of prolonged qt-qtc ≥
             450 ms.

         18. pre-existing neuropathies of any type ≥ grade 2.

         19. hypersensitivity to the active substance or to any of its excipients (macrogol
             glycerol ricinoleate and ethanol).

         20. patients who require or are being treated with potent cyp3a4 inhibitors and inducers.

         21. patients who for any reason should not be included in the study according to the
             evaluation of the research team.
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
June 25, 2024, noon	usa	1. patients participating in some other clinical trial for covid-19 infection. 2. patients who are receiving treatment with antivirals, interleukin 6 receptor inhibitors or immunomodulatory drugs for covid-19. 3. patients who are receiving treatment with chloroquine and derivatives. 4. evidence of multi-organ failure. 5. patients who require support with mechanical ventilation (invasive or non-invasive) at the time of inclusion. 6. d-dimer\> 4 x unl. 7. hb \<9 g / dl. 8. neutrophils \<1000 / mm3. 9. platelets \<100,000 / mm3. 10. lymphopenia \<800 / μl. 11. got / gpt\> 3 x unl. 12. bilirubin\> 1 x unl. 13. cpk\> 2.5 x unl. 14. creatinine clearance \<30ml / min. 15. troponin elevation\> 1.5 x uln. 16. clinically relevant heart disease (nyha\> 2). 17. clinically relevant arrhythmia or previous history / presence of prolonged qt-qtc ≥ 450 ms. 18. pre-existing neuropathies of any type ≥ grade 2. 19. hypersensitivity to the active substance or to any of its excipients (macrogol glycerol ricinoleate and ethanol). 20. patients who require or are being treated with potent cyp3a4 inhibitors and inducers. 21. patients who for any reason should not be included in the study according to the evaluation of the research team.	1. patients participating in some other clinical trial for covid-19 infection. 2. patients who are receiving treatment with antivirals, interleukin 6 receptor inhibitors or immunomodulatory drugs for covid-19. 3. patients who are receiving treatment with chloroquine and derivatives. 4. evidence of multi-organ failure. 5. patients who require support with mechanical ventilation (invasive or non-invasive) at the time of inclusion. 6. d-dimer\> 4 x unl. 7. hb \<9 g / dl. 8. neutrophils \<1000 / mm3. 9. platelets \<100,000 / mm3. 10. lymphopenia \<800 / μl. 11. got / gpt\> 3 x unl. 12. bilirubin\> 1 x unl. 13. cpk\> 2.5 x unl. 14. creatinine clearance \<30ml / min. 15. troponin elevation\> 1.5 x uln. 16. clinically relevant heart disease (nyha\> 2). 17. clinically relevant arrhythmia or previous history / presence of prolonged qt-qtc ≥ 450 ms. 18. pre-existing neuropathies of any type ≥ grade 2. 19. hypersensitivity to the active substance or to any of its excipients (macrogol glycerol ricinoleate and ethanol). 20. patients who require or are being treated with potent cyp3a4 inhibitors and inducers. 21. patients who for any reason should not be included in the study according to the evaluation of the research team.
Nov. 16, 2021, 6:30 p.m.	usa	patients participating in some other clinical trial for covid-19 infection. patients who are receiving treatment with antivirals, interleukin 6 receptor inhibitors or immunomodulatory drugs for covid-19. patients who are receiving treatment with chloroquine and derivatives. evidence of multi-organ failure. patients who require support with mechanical ventilation (invasive or non-invasive) at the time of inclusion. d-dimer> 4 x unl. hb <9 g / dl. neutrophils <1000 / mm3. platelets <100,000 / mm3. lymphopenia <800 / μl. got / gpt> 3 x unl. bilirubin> 1 x unl. cpk> 2.5 x unl. creatinine clearance <30ml / min. troponin elevation> 1.5 x uln. clinically relevant heart disease (nyha> 2). clinically relevant arrhythmia or previous history / presence of prolonged qt-qtc ≥ 450 ms. pre-existing neuropathies of any type ≥ grade 2. hypersensitivity to the active substance or to any of its excipients (macrogol glycerol ricinoleate and ethanol). patients who require or are being treated with potent cyp3a4 inhibitors and inducers. patients who for any reason should not be included in the study according to the evaluation of the research team.	patients participating in some other clinical trial for covid-19 infection. patients who are receiving treatment with antivirals, interleukin 6 receptor inhibitors or immunomodulatory drugs for covid-19. patients who are receiving treatment with chloroquine and derivatives. evidence of multi-organ failure. patients who require support with mechanical ventilation (invasive or non-invasive) at the time of inclusion. d-dimer> 4 x unl. hb <9 g / dl. neutrophils <1000 / mm3. platelets <100,000 / mm3. lymphopenia <800 / μl. got / gpt> 3 x unl. bilirubin> 1 x unl. cpk> 2.5 x unl. creatinine clearance <30ml / min. troponin elevation> 1.5 x uln. clinically relevant heart disease (nyha> 2). clinically relevant arrhythmia or previous history / presence of prolonged qt-qtc ≥ 450 ms. pre-existing neuropathies of any type ≥ grade 2. hypersensitivity to the active substance or to any of its excipients (macrogol glycerol ricinoleate and ethanol). patients who require or are being treated with potent cyp3a4 inhibitors and inducers. patients who for any reason should not be included in the study according to the evaluation of the research team.
Oct. 26, 2020, 11:31 p.m.	usa	1. patients participating in some other clinical trial for covid-19 infection. 2. patients who are receiving treatment with antivirals, interleukin 6 receptor inhibitors or immunomodulatory drugs for covid-19. 3. patients who are receiving treatment with chloroquine and derivatives. 4. evidence of multi-organ failure. 5. patients who require support with mechanical ventilation (invasive or non-invasive) at the time of inclusion. 6. d-dimer> 4 x unl. 7. hb <9 g / dl. 8. neutrophils <1000 / mm3. 9. platelets <100,000 / mm3. 10. lymphopenia <800 / μl. 11. got / gpt> 3 x unl. 12. bilirubin> 1 x unl. 13. cpk> 2.5 x unl. 14. creatinine clearance <30ml / min. 15. troponin elevation> 1.5 x uln. 16. clinically relevant heart disease (nyha> 2). 17. clinically relevant arrhythmia or previous history / presence of prolonged qt-qtc ≥ 450 ms. 18. pre-existing neuropathies of any type ≥ grade 2. 19. hypersensitivity to the active substance or to any of its excipients (macrogol glycerol ricinoleate and ethanol). 20. patients who require or are being treated with potent cyp3a4 inhibitors and inducers. 21. patients who for any reason should not be included in the study according to the evaluation of the research team.	1. patients participating in some other clinical trial for covid-19 infection. 2. patients who are receiving treatment with antivirals, interleukin 6 receptor inhibitors or immunomodulatory drugs for covid-19. 3. patients who are receiving treatment with chloroquine and derivatives. 4. evidence of multi-organ failure. 5. patients who require support with mechanical ventilation (invasive or non-invasive) at the time of inclusion. 6. d-dimer> 4 x unl. 7. hb <9 g / dl. 8. neutrophils <1000 / mm3. 9. platelets <100,000 / mm3. 10. lymphopenia <800 / μl. 11. got / gpt> 3 x unl. 12. bilirubin> 1 x unl. 13. cpk> 2.5 x unl. 14. creatinine clearance <30ml / min. 15. troponin elevation> 1.5 x uln. 16. clinically relevant heart disease (nyha> 2). 17. clinically relevant arrhythmia or previous history / presence of prolonged qt-qtc ≥ 450 ms. 18. pre-existing neuropathies of any type ≥ grade 2. 19. hypersensitivity to the active substance or to any of its excipients (macrogol glycerol ricinoleate and ethanol). 20. patients who require or are being treated with potent cyp3a4 inhibitors and inducers. 21. patients who for any reason should not be included in the study according to the evaluation of the research team.